A Double-Blind, Randomized, Single Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment
Latest Information Update: 01 Nov 2018
At a glance
- Drugs Ulobetasol (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Therapeutics Incorporated
- 17 Oct 2012 New trial record